Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Targeted therapy versus standards of care in metastatic NSCLC

Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, provides an overview of the Phase II randomized UNICANCER/IFCT1301-SAFIR02-LUNG intergroup trial (NCT02117167) comparing targeted therapy to standard of care (SoC) in patients with metastatic non-small cell lung cancer (NSCLC). 175 patients either received eight possible targeted therapies or the SoC, which mainly consisted of pemetrexed therapy, and targeted therapies failed to reach the primary and secondary endpoints of progression-free survival (PFS) and overall survival (OS) respectively. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.